Sarepta Therapeutics, Inc.
NASDAQ:SRPTBiotechnology
+$0.29 today
- Market cap
- $1.56B
- Beta
- 0.20
- P/E (TTM)
- 27.8
- EPS (TTM)
- $0.62
Volume 1.86M
Average 3.08M
SRPT Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Sarepta Therapeutics, Inc.NASDAQ: SRPT
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables growth accelerates
Q1 FY2026 accounts payables of $210.47M (cash outflow) rose 260.8% year over year, ahead of the -42.1% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at -10.9% a year.
Context
- Accounts payables amounted to 4.7% of revenue in FY2025, down 1.1 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +260.8% holds above the trailing-twelve-month pace of -42.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 104.27M USD
- Year-over-year change
- -5.8%
- 4-year CAGR
- +45.5%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 104.27M | -5.8% |
| FY2024 | 2024-12-31 | 110.65M | +320.7% |
| FY2023 | 2023-12-31 | (50.14M) | -134.0% |
| FY2022 | 2022-12-31 | 147.57M | +533.4% |
| FY2021 | 2021-12-31 | 23.3M | — |
Accounts Payables vs competitors
How SRPT compares with its peers on the latest reported figures
- SRPT's LTM Mar 2026 accounts payables of $39.15M is the 2nd largest of the 11 companies compared; the peer median is $1.93M.
- Its year-over-year change of -42.1% is the 5th highest of 10, against a peer median of -66.8%.
- Accounts payables amounts to 1.8% of revenue for SRPT, versus a peer median of 1.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $65.76M | -237.3% | -26.8% | 1.4% | |
| LTM Mar 2026 | $39.15M | -42.1% | -10.9% | 1.8% | |
| LTM Jun 2026 | $23.17M | +98.6% | — | — | |
| LTM Sep 2026 | $11.71M | -66.8% | — | 1.2% | |
| LTM Mar 2026 | $6.44M | +1108.8% | — | 9.7% | |
| LTM Mar 2026 | $4.81M | +99.3% | — | 6.7% | |
| LTM Mar 2026 | $2.28M | +126.9% | -5.9% | — | |
| LTM Mar 2026 | $2.06M | -230.7% | -12.7% | — | |
| LTM Mar 2026 | $1.59M | -99.4% | +70.5% | — | |
| LTM Mar 2026 | $767K | -76.5% | -40.7% | — | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding SRPT) | $1.93M | -66.8% | -12.7% | 1.4% | |
Competitors are the stored peer set for SRPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (418.78M) | (703.49M) | (535.98M) | 235.24M | (713.41M) |
| Depreciation & Amortization | 38.02M | 41.86M | 44.4M | 37.72M | 44.52M |
| Deferred Income Tax | 15.81M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 113.94M | 233.02M | 182.51M | 184.3M | 123.4M |
| Change in Working Capital | (98.17M) | (39.47M) | (481.09M) | (716.61M) | 78.04M |
| Accounts Receivables | (51.65M) | (61.64M) | (185.7M) | (201.66M) | 203.76M |
| Inventory | (83.77M) | (50.78M) | (147.71M) | (395.17M) | (301.09M) |
| Accounts Payables | 23.3M | 147.57M | (50.14M) | 110.65M | 104.27M |
| Other Working Capital | 13.96M | (74.62M) | (97.54M) | (230.42M) | 71.11M |
| Other Non-Cash Items | (94M) | 142.73M | 289.16M | 53.56M | 261.98M |
| Operating Cash Flow | (443.17M) | (325.35M) | (500.99M) | (205.79M) | (205.48M) |
| Capital Expenditures | (38.49M) | (32.25M) | (87.35M) | (146.96M) | (101.97M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (29.99M) | (1.94B) | (2.05B) | (1.1B) | (44.66M) |
| Sales of Investments | 466M | 923.22M | 1.87B | 2B | 469.97M |
| Other Investing Activities | 97.89M | (1.43M) | 90.76M | (10M) | (253.7M) |
| Investing Cash Flow | 495.41M | (1.05B) | (165.8M) | 755.56M | 69.64M |
| Debt Repayment | 0 | 304.17M | 0 | (68K) | (162.59M) |
| Common Stock Issued | 548.53M | 0 | 0 | 0 | 36.32M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (25.01M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 13.04M | (71.66M) | 125M | 124.87M | (17.06M) |
| Financing Cash Flow | 561.57M | 232.51M | 125M | 124.81M | (168.34M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 613.81M | (1.14B) | (541.79M) | 674.58M | (304.18M) |
| Free Cash Flow | (481.66M) | (357.6M) | (588.34M) | (352.74M) | (307.45M) |
Sarepta Therapeutics, Inc.
NASDAQ:SRPT
Intrinsic Alpha fair value
Locked
Current Price
$14.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.